TGTX's balance sheet roughly doubled in total assets while revenue declined substantially and operating expenses expanded meaningfully, signaling a company in aggressive commercial build-out mode with deteriorating near-term fundamentals.
Revenue declined substantially year-over-year (from $6.7M to $2.8M), which is a material negative signal for a company that appears to be in early commercialization — suggesting product ramp is not yet offsetting base revenue erosion. Cash and equivalents fell by more than half (from $179.9M to $79.1M), a concrete liquidity trigger, even as total assets grew to $1.1B — implying the asset base expansion is being driven by non-cash items rather than cash generation. Investors should closely monitor the company's cash runway given the combination of declining cash, expanding cost structure, and negative operating cash flow, even though operating cash burn improved modestly to -$24.8M.
TGTX's cost structure expanded substantially across both R&D (from $94.3M to $160.2M, roughly +70%) and SG&A (from $154.3M to $232.0M, up approximately 50%), reflecting a company scaling commercial and development infrastructure simultaneously. Total assets grew meaningfully to $1.1B and total debt rose modestly to $100.4M (+41.1%), while current liabilities grew notably to $153.8M — indicating the balance sheet is being leveraged to fund operations. The overall picture is one of a pre-profitability biotech absorbing heavy investment-phase costs against a shrinking revenue base, with cash declining sharply; the key investor question is whether the commercial asset base will generate sufficient future revenue to justify the current spending trajectory before cash reserves require replenishment.
Asset base grew 84.1% — expansion through organic growth, acquisitions, or capital deployment.
R&D investment increased 69.9% — signals commitment to future product development, though near-term margin impact.
Current liabilities surged 69.6% — significant near-term obligations; verify ability to meet short-term debt.
Revenue declined 58.4% — significant demand weakness or market share loss warrants investigation.
Cash declined 56% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
SG&A up 50.4% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Debt increased 41.1% — substantial leverage increase; assess whether deployed for growth or covering losses.
Operating cash flow surged 38.9% — exceptional cash generation, highest quality earnings signal.
Interest costs rose 23.8% — monitor debt levels and coverage ratio in rising rate environment.
Liabilities increased 16.9% — monitor debt-to-equity ratio and interest coverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →